Abivax (ABVX) has appointed Michael Nesrallah as its chief commercial officer, Nesrallah will lead global commercial strategy and launch preparation as the company advances toward potential regulatory approval and market entry for obefazimod, bringing more than 20 years of global biopharmaceutical leadership experience with expertise in gastroenterology and immunology. Prior to joining Abivax, he held several senior leadership roles at Takeda (TAK).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax price target raised to $148 from $142 at Barclays
- Abivax Posts 2025 Results, Confirms Phase 3 Ulcerative Colitis Timeline and Expands Leadership Team
- – Abivax SA American Depositary Shares options imply 8.3% move in share price post-earnings
- U.S. Chess Champion Hikaru Stays Ahead of the S&P Thanks to Tech, Oil and Health Stocks
- Abivax SA Sponsored ADR (ABVX) Q4 Earnings Cheat Sheet